Clostridium butyricum and Clostridium tyrobutyricum: angel or devil for necrotizing enterocolitis?
丁酸梭菌和酪酸梭菌:坏死性小肠结肠炎的天使还是魔鬼?
阅读:1
作者:Ruizhi Tao # ,Gangfan Zong # ,Yehua Pan ,Hongxing Li ,Peng Cheng ,Rui Deng ,Wenxing Chen ,Aiyun Wang ,Shishan Xia ,Weibing Tang ,Yin Lu ,Zhonghong Wei
| 期刊: | mSystems | 影响因子: | 5.000 |
| 时间: | 2023 | 起止号: | 2023 Dec 21;8(6):e0073223. |
| doi: | 10.1128/msystems.00732-23 | 种属: | Human |
| 方法学: | FCM、IF、IHC-P、WB | 靶点: | CADH1 |
| 研究方向: | 免疫 | 疾病类型: | 肠炎 |
Abstract
This study sheds light on that treatment with Clostridium tyrobutyricum but not Clostridium butyricum is entitled to protect against necrotizing enterocolitis (NEC) development potentially. The mechanisms behind the opposite effect on NEC may result in different modulation on the level of Akkermansia muciniphila, which is deeply associated with intestinal homoeostasis. Briefly, through improving the abundance of A. muciniphila to alleviate intestinal inflammation and enhance intestinal barrier integrity, C. tyrobutyricum supplement may become a promising therapy for NEC.
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。